Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
3.020
+0.095 (3.25%)
At close: May 12, 2025, 4:00 PM
3.000
-0.020 (-0.66%)
After-hours: May 12, 2025, 7:48 PM EDT
Cytek Biosciences Revenue
Cytek Biosciences had revenue of $41.46M in the quarter ending March 31, 2025, a decrease of -7.59%. This brings the company's revenue in the last twelve months to $197.05M, down -1.86% year-over-year. In the year 2024, Cytek Biosciences had annual revenue of $200.45M with 3.85% growth.
Revenue (ttm)
$197.05M
Revenue Growth
-1.86%
P/S Ratio
1.99
Revenue / Employee
$304,090
Employees
648
Market Cap
382.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 200.45M | 7.44M | 3.85% |
Dec 31, 2023 | 193.02M | 28.98M | 17.67% |
Dec 31, 2022 | 164.04M | 36.09M | 28.20% |
Dec 31, 2021 | 127.95M | 35.11M | 37.82% |
Dec 31, 2020 | 92.84M | 34.96M | 60.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2011 | Pro | Pro | Pro |
Dec 31, 2010 | Pro | Pro | Pro |
Dec 31, 2009 | Pro | Pro | Pro |
Dec 31, 2007 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CTKB News
- 1 day ago - Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Cytek Biosciences Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 7 days ago - Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued? - Seeking Alpha
- 13 days ago - Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025 - GlobeNewsWire
- 14 days ago - Why Cytek Biosciences Should Beat Q1 Earnings Expectations - Seeking Alpha
- 18 days ago - Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025 - GlobeNewsWire
- 7 weeks ago - Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System - GlobeNewsWire
- 2 months ago - Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha